Preclinical studies in melanoma-bearing syngeneic mice revealed that the concomitant blockade of CD3E and TRP-1 facilitates tumor shrinkage through the enhanced influx of innate and adaptive immune cells [61]. This evidence concerns the gene CD3E and melanoma.